These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 23803800

  • 1. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain.
    Carrasco JL, Álvarez E, Olivares JM, Rejas J.
    Actas Esp Psiquiatr; 2013; 41(3):164-74. PubMed ID: 23803800
    [Abstract] [Full Text] [Related]

  • 2. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain.
    De Salas-Cansado M, Álvarez E, Olivares JM, Carrasco JL, Ferro MB, Rejas J.
    Soc Psychiatry Psychiatr Epidemiol; 2013 Jun; 48(6):985-96. PubMed ID: 23086587
    [Abstract] [Full Text] [Related]

  • 3. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
    Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ.
    Int Clin Psychopharmacol; 2012 May; 27(3):142-50. PubMed ID: 22302014
    [Abstract] [Full Text] [Related]

  • 4. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain.
    De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J.
    Clinicoecon Outcomes Res; 2012 May; 4():157-68. PubMed ID: 22745564
    [Abstract] [Full Text] [Related]

  • 5. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
    Vlahiotis A, Devine ST, Eichholz J, Kautzner A.
    J Manag Care Pharm; 2011 Mar; 17(2):123-32. PubMed ID: 21348545
    [Abstract] [Full Text] [Related]

  • 6. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL, Kindermann SL, Hou Q, Thase ME.
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [Abstract] [Full Text] [Related]

  • 7. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
    Álvarez E, Olivares JM, Carrasco JL, López-Gómez V, Rejas J.
    Ann Gen Psychiatry; 2015 Jan; 14(1):2. PubMed ID: 25632294
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
    Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G.
    Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective.
    Darbà J, Kaskens L, Pérez C, Álvarez E, Navarro-Artieda R, Sicras-Mainar A.
    Adv Ther; 2014 Jan; 31(1):1-29. PubMed ID: 24390901
    [Abstract] [Full Text] [Related]

  • 10. Pregabalin: a review of its use in adults with generalized anxiety disorder.
    Frampton JE.
    CNS Drugs; 2014 Sep; 28(9):835-54. PubMed ID: 25149863
    [Abstract] [Full Text] [Related]

  • 11. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder.
    Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S.
    World J Biol Psychiatry; 2012 Oct; 13(7):510-6. PubMed ID: 22059936
    [Abstract] [Full Text] [Related]

  • 12. Pregabalin versus sertraline in generalized anxiety disorder. An open label study.
    Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS, Boskovic K, Jovicevic M.
    Eur Rev Med Pharmacol Sci; 2015 Oct; 19(11):2120-4. PubMed ID: 26125277
    [Abstract] [Full Text] [Related]

  • 13. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK, Kruzikas DT, McLaughlin TP.
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [Abstract] [Full Text] [Related]

  • 14. [Generalized anxiety disorder with comorbidity. Treatment with pregabalin].
    Lauer D, Hölzel L, Hornyak M.
    Nervenarzt; 2006 Nov; 77(11):1363, 1365-7. PubMed ID: 16786360
    [Abstract] [Full Text] [Related]

  • 15. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A, Saldaña MT, Pérez C, Masramón X, Rejas J.
    Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
    Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC.
    J Clin Psychiatry; 2006 May; 67(5):771-82. PubMed ID: 16841627
    [Abstract] [Full Text] [Related]

  • 17. An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder.
    Schwartz TL, Nasra GS, Ashton AK, Kang D, Kumaresan H, Chilton M, Bertone F.
    Ann Clin Psychiatry; 2007 May; 19(1):25-30. PubMed ID: 17453658
    [Abstract] [Full Text] [Related]

  • 18. Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: a retrospective cohort study.
    Berger A, Edelsberg J, Treglia M, Alvir JM, Oster G.
    BMC Psychiatry; 2012 Oct 23; 12():177. PubMed ID: 23088742
    [Abstract] [Full Text] [Related]

  • 19. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE, Regan TS, Chiao E, Sarnes MW.
    Am J Manag Care; 2005 Oct 23; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [Abstract] [Full Text] [Related]

  • 20. Cost comparison of adding pregabalin or gabapentin for the first time to the therapy of patients with painful axial radiculopathy treated in Spain.
    Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, Planas-Comes A.
    Clin Exp Rheumatol; 2013 Oct 23; 31(3):372-81. PubMed ID: 23432967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.